Glenmark Pharmaceuticals Ltd (Glenmark), announced the launch of its novel, patent protected and globally-researched sodium glucose co-transporter (SGLT2)inhibitor Remogliflozinetabonate(Remogliflozin) in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults.

SGLT2 inhibitors are novel anti-diabetic drugs that help achieve glycemic control by acting on the SGLT2 receptors in the proximal convoluted tubule of the kidney, thereby preventing renal reabsorption of glucose and promoting excretion of glucose in the urine. Along with providing glycemic control, SGLT2 inhibitors help induce weight loss and reduce cardiovascular risks.

Glenmark is the first company in the world to launch Remogliflozin and India is the first country to get access to this innovative drug. Glenmark has launched Remogliflozin in India under brand names “Remo” and “Remozen”.

The company has launched Remogliflozin at a breakthrough price of Rs. 12.50 per tablet, twice daily, which is over 50% lower than the existing SGLT2 inhibitors available in India.  Currently, the average per day therapy cost of SGLT2 inhibitors in India is about Rs. 55.